Page last updated: 2024-11-06

darodipine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Darodipine is a calcium channel blocker that has been investigated for its potential therapeutic effects in various conditions. However, it has not been approved for clinical use. Its synthesis involves complex chemical reactions. Research on darodipine has explored its potential in treating cardiovascular diseases, such as hypertension and angina. The molecule is studied due to its ability to relax blood vessels, which can help lower blood pressure and improve blood flow. Darodipine's effects on the cardiovascular system are thought to be mediated through its interaction with calcium channels, inhibiting the influx of calcium ions into cells. Darodipine's importance lies in its potential to offer a new therapeutic option for patients with cardiovascular disorders, particularly those with high blood pressure. However, further research is needed to fully understand its safety and efficacy.'

darodipine: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID51701
CHEMBL ID2104154
SCHEMBL ID44696
MeSH IDM0106570

Synonyms (37)

Synonym
dazodipine
darodipine
py-108068
72803-02-2
darodipine (usan/inn)
D03655
3,5-pyridinedicarboxylic acid, 4-(4-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-, diethyl ester
diethyl 4-(4-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate
py 108-068
darodipino [spanish]
dazodipin
darodipine [usan:inn]
darodipinum [latin]
diethyl 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
darodipino
unii-n4al7x96gl
darodipinum
n4al7x96gl ,
py-108-068
CHEMBL2104154
darodipine [mart.]
darodipine [usan]
darodipine [inn]
SCHEMBL44696
4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydro-pyridine-3,5-dicarboxylic acid diethyl ester
QERUYFVNIOLCHV-UHFFFAOYSA-N
DTXSID90223125
AC-26452
AKOS025401865
DB09234
diethyl4-(2,1,3-benzoxadiazol-7-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
HY-U00086
Q5224165
py 108-068;py-108068
(3-chlorophenyl)piperidin-4-yl-methanonehydrochloride
diethyl 4-(benzo[c][1,2,5]oxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid 3,5-diethyl ester

Research Excerpts

Overview

Darodipine is a new light stable dihydropyridine calcium antagonist.

ExcerptReferenceRelevance
"Darodipine is a new light stable dihydropyridine calcium antagonist. "( Effect of calcium antagonist darodipine on the isolated human heart.
Carey, B; Ginsburg, R; Zera, P, 1986
)
2

Treatment

Darodipine treatment reduced blood pressure in SHR. Treatment increased the number and the average length of alkaline phosphatase-reactive capillaries in old rats. Pretreatment also prevented APD prolongation caused by OFR.

ExcerptReferenceRelevance
"Darodipine treatment reduced blood pressure in SHR."( Influence of treatment with the calcium channel blocker darodipine (PY 108-068) on the morphology of pial and coronary arteries in spontaneously hypertensive rats.
Amenta, F; Ferrante, F; Ricci, A; Rossodivita, I, 1994
)
1.26
"Treatment with darodipine increased the number and the average length of alkaline phosphatase-reactive capillaries and reduced the intercapillary distance and the diameter of cerebral capillaries in old rats."( Effect of long-term treatment with the dihydropyridine-type calcium channel blocker darodipine (PY 108-068) on the cerebral capillary network in aged rats.
Amenta, F; Ferrante, F; Mancini, M; Sabbatini, M; Vega, JA; Zaccheo, D, 1995
)
0.86
"Pretreatment with darodipine also prevented APD prolongation caused by OFR (137+/-12 ms after DHF vs 117+/-6 ms before DHF n=14, not significant) but not the decrease of MDP (-63.4+/-2.5 mV after DHF vs -70.9+/-1.0 mV before DHF, P<0.05)."( Protective effect of darodipine, a calcium antagonist, on rat cardiomyocytes against oxygen radical-mediated injury.
Barbieri, M; Cerbai, E; Matucci, R; Mugelli, A; Ottaviani, MF, 1997
)
0.94

Dosage Studied

ExcerptRelevanceReference
" The absence of reflex tachycardia found in previous chronic oral dosing studies with this drug appears to take some days to develop in humans."( PY 108-068--acute effects of a single oral dose in chronic stable angina.
de Buitleir, M; Krikler, DM; Krikler, S, 1986
)
0.27
" PY decreased the maximum inotropic and chronotropic responses to isoprenaline and caused a dose-response parallel shift of the Ca dose-response curve."( Inotropic and electrophysiological effects of PY 108-068 on isolated cardiac preparations.
Delgado, C; Diez, J; Tamargo, J; Tejerina, MT, 1984
)
0.27
" Following sinoaortic baroreflex denervation the dose-response curve for the calcium antagonist-induced fall in blood pressure and total peripheral resistance was shifted to the left."( Calcium antagonists: systemic and regional haemodynamic effects in conscious spontaneously hypertensive rats (SHR).
Nievelstein, HM; Smits, JF; Struyker-Boudier, HA; van Essen, H, 1984
)
0.27
"The relaxant effects of five organic calcium antagonists (nicardipine, diltiazem, PY 108068, verapamil and bepridil) on guinea-pig isolated trachea were tested against contractions induced by acetylcholine, histamine, 5-hydroxytryptamine, potassium chloride (KCl) and tetraethylammonium (TEA) in a medium containing the normal amount of calcium and against calcium dose-response curves in a calcium-free, potassium-enriched medium."( Effects of five different organic calcium antagonists on guinea-pig isolated trachea.
Advenier, C; Cerrina, J; Duroux, P; Floch, A; Renier, A, 1984
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (69)

TimeframeStudies, This Drug (%)All Drugs %
pre-199049 (71.01)18.7374
1990's20 (28.99)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 15.04

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index15.04 (24.57)
Research Supply Index4.48 (2.92)
Research Growth Index4.34 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (15.04)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials10 (12.99%)5.53%
Reviews2 (2.60%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other65 (84.42%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]